Mayo T, Armstrong AW, Kircik L, Silverberg J, Blauvelt A, Esdalie B, Schneider S, Mark T, Gooderham M, Alexis AF. Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis. J of Skin [Internet]. 2022 Nov. 16 [cited 2024 Jul. 3];6(6):s74. Available from: https://jofskin.org/33014/index.php/skin/article/view/1831